ES2329553T3 - Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. - Google Patents
Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. Download PDFInfo
- Publication number
- ES2329553T3 ES2329553T3 ES01994318T ES01994318T ES2329553T3 ES 2329553 T3 ES2329553 T3 ES 2329553T3 ES 01994318 T ES01994318 T ES 01994318T ES 01994318 T ES01994318 T ES 01994318T ES 2329553 T3 ES2329553 T3 ES 2329553T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- substituted
- case
- independently selected
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- -1 -OH Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto de la fórmula (I): **(Ver fórmula)** o un estereoisómero o una forma de sal farmacéuticamente aceptable del mismo, en el que: b es un enlace sencillo, donde los hidrógenos puente son cis o trans; X es -CH2-, R1 se selecciona entre H, alquilo C1-5, alquenilo C2-5, alquinilo C2-5, cicloalquilo C3-6, -(alquil C1-3) cicloalquilo C3-6, -(alquenil C2-3)cicloalquilo C3-6 y -(alquinil C2-3)cicloalquilo C3-6, R6a es H o alquilo C1-4; R6b es H; como alternativa, R6a y R6b se toman juntos para formar =O o =S; R7 y R9, en cada caso, se seleccionan independientemente entre H, halo, -CF3, -OCF3, -OH, -CN, -NO2, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, alcoxi C1-4 y (haloalquil C1-4)oxi; R8 se selecciona entre H; fenilo sustituido con O-S R33; y -NR12R13; R12, en cada caso, se selecciona independientemente entre alquilo C1-4 sustituido con 0-1 R12a, alquenilo C2-4 sustituido con 0-1 R12a, alquinilo C2-4 sustituido con 0-1 R12a, cicloalquilo C3-6 sustituido con 0-3 R33, arilo sustituido con 0-5 R33; resto carbocíclico C3-10 sustituido con 0-3 R33 y sistema de anillos heterocíclicos de 5-10 miembros que contiene 1-4 heteroátomos seleccionados entre el grupo constituido por N, O y S sustituido con 0-3 R31; R12a, en cada caso, se selecciona independientemente entre fenilo sustituido con 0-5 R33; resto carbocíclico C3-10 sustituido con 0-3 R33 y sistema de anillos heterocíclicos de 5-10 miembros que contiene de 1-4 heteroátomos seleccionados entre el grupo constituido por N, O y S sustituido con 0-3 R31; R13, en cada caso, se selecciona independientemente entre H, alquilo C1-4, alquenilo C2-4 y alquinilo C2-4; como alternativa, R12 y R13, cuando se unen a N, pueden combinarse para formar un anillo heterocíclico bicíclico de 9 ó 10 miembros que contiene 1-3 heteroátomos seleccionados entre el grupo constituido por N, O y S, donde dicho sistema de anillos heterocíclicos bicíclico está insaturado o parcialmente saturado, donde dicho sistema de anillos heterocíclicos bicíclico está sustituido con 0-3 R16; R16, en cada caso, se selecciona independientemente entre H, OH, halo, CN, NO2, CF3, SO2R45, NR46R47, -C(=O) H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, (haloalquil C1-3)-oxi-, (alquiloxi C1-3)-, y =O; R31, en cada caso, se selecciona independientemente entre H, OH, halo, CF3, SO2R45, NR46R47, alquilo C1-4 y =O; R33, en cada caso, se selecciona independientemente entre H, OH, halo, CN, NO2, CF3, SO2R 45, NR46R47, -C(=O)H, =O, fenilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, haloalquilo C1-4, (haloalquil C1-4)-oxi-, (alquiloxi C1-4)-, (alquiltio C1-4)-, (alquil C1-4)-C(=O)-, (alquil C1-4)-C(=O)NH-, (alquil C1-4)-OC(=O)-, (alquil C1-4)-C(=O)O-, (cicloalquil C3-6)-oxi-, (cicloalquilmetil C3-6)-oxi-; alquilo C1-6 sustituido con OH, metoxi, etoxi, propoxi, butoxi, -SO2R45, -NR46R47, NR46R47C(=O)- o (alquil C1-4)CO2-; y alquenilo C2-6 sustituido con OH, metoxi, etoxi, propoxi, butoxi, -SO2R45, -NR46R47, NR46R47C(=O)-, o (alquil C1-4)CO2-; R45 es alquilo C1-4; R46, en cada caso, se selecciona independientemente entre H y alquilo C1-4; R47, en cada caso, se selecciona independientemente entre H, alquilo C1-4, -C(=O)NH(alquilo C1-4), -SO2(alquilo C1-4), -C(=O)O(alquilo C1-4), -C(=O)( alquilo C1-4) y -C(=O)H; n es 1 ó 2; m es 1 ó 2; y n más m es 2, 3 ó 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25674500P | 2000-12-20 | 2000-12-20 | |
| US256745P | 2000-12-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2329553T3 true ES2329553T3 (es) | 2009-11-27 |
| ES2329553T4 ES2329553T4 (es) | 2010-12-07 |
Family
ID=22973430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01994318T Expired - Lifetime ES2329553T4 (es) | 2000-12-20 | 2001-12-19 | Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6777406B2 (es) |
| EP (1) | EP1399445B9 (es) |
| JP (1) | JP4386639B2 (es) |
| KR (1) | KR20030070590A (es) |
| AT (1) | ATE438646T1 (es) |
| AU (1) | AU2002246726B2 (es) |
| BG (1) | BG107863A (es) |
| BR (1) | BR0116348A (es) |
| CA (1) | CA2432181C (es) |
| CZ (1) | CZ20031707A3 (es) |
| DE (1) | DE60139511D1 (es) |
| EE (1) | EE200300303A (es) |
| ES (1) | ES2329553T4 (es) |
| HU (1) | HUP0303530A3 (es) |
| IL (1) | IL156261A0 (es) |
| IS (1) | IS6851A (es) |
| MX (1) | MXPA03005355A (es) |
| NO (1) | NO20032798L (es) |
| PL (1) | PL366627A1 (es) |
| RU (1) | RU2003121306A (es) |
| SK (1) | SK7032003A3 (es) |
| WO (1) | WO2002059124A2 (es) |
| ZA (1) | ZA200304304B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759405B2 (en) | 2000-11-03 | 2004-07-06 | Wyeth | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| US6777407B2 (en) | 2000-11-03 | 2004-08-17 | Wyeth | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| AR031199A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados |
| TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307540A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| JP5173190B2 (ja) | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| US20070021612A1 (en) * | 2004-11-04 | 2007-01-25 | University Of Notre Dame Du Lac | Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof |
| US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
| GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
| EP1998781A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Treatment of pain |
| JP2009531435A (ja) * | 2006-03-24 | 2009-09-03 | ワイス | うつ病の治療用の新規な治療組み合わせ |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| WO2011044506A2 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| BR112013001613A2 (pt) * | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
| US9321740B2 (en) | 2011-01-26 | 2016-04-26 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| WO2012154679A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
| US9290472B2 (en) | 2011-05-06 | 2016-03-22 | Zafgen, Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| AU2013209719A1 (en) | 2012-01-18 | 2014-08-07 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| BR112015010225A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos e seus métodos de produção e utilização |
| CN104918928A (zh) | 2012-11-05 | 2015-09-16 | 扎夫根股份有限公司 | 三环化合物及其制备方法和用途 |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2981266B1 (en) * | 2013-03-04 | 2018-01-03 | Daya CNS LLC | Pentacyclic pyridoindolobenz[b,d]azepine derivatives and uses thereof |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| CN109897039B (zh) * | 2019-03-13 | 2021-03-30 | 中国科学院化学研究所 | 一种制备吡咯并[3,2,1-ij]喹啉酮化合物的方法 |
| WO2022221415A2 (en) * | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4013652A (en) | 1972-06-19 | 1977-03-22 | Endo Laboratories, Inc. | Pyridopyrrolobenzoxazine |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| HUT61548A (en) | 1990-08-27 | 1993-01-28 | Sandoz Ag | Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds |
-
2001
- 2001-12-19 MX MXPA03005355A patent/MXPA03005355A/es unknown
- 2001-12-19 CA CA002432181A patent/CA2432181C/en not_active Expired - Fee Related
- 2001-12-19 AT AT01994318T patent/ATE438646T1/de not_active IP Right Cessation
- 2001-12-19 IL IL15626101A patent/IL156261A0/xx unknown
- 2001-12-19 EE EEP200300303A patent/EE200300303A/xx unknown
- 2001-12-19 EP EP01994318A patent/EP1399445B9/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002559426A patent/JP4386639B2/ja not_active Expired - Fee Related
- 2001-12-19 PL PL01366627A patent/PL366627A1/xx unknown
- 2001-12-19 CZ CZ20031707A patent/CZ20031707A3/cs unknown
- 2001-12-19 WO PCT/US2001/049380 patent/WO2002059124A2/en not_active Ceased
- 2001-12-19 SK SK703-2003A patent/SK7032003A3/sk unknown
- 2001-12-19 RU RU2003121306/04A patent/RU2003121306A/ru not_active Application Discontinuation
- 2001-12-19 KR KR10-2003-7008267A patent/KR20030070590A/ko not_active Withdrawn
- 2001-12-19 AU AU2002246726A patent/AU2002246726B2/en not_active Ceased
- 2001-12-19 ES ES01994318T patent/ES2329553T4/es not_active Expired - Lifetime
- 2001-12-19 US US10/026,993 patent/US6777406B2/en not_active Expired - Lifetime
- 2001-12-19 DE DE60139511T patent/DE60139511D1/de not_active Expired - Lifetime
- 2001-12-19 BR BR0116348-5A patent/BR0116348A/pt not_active Application Discontinuation
- 2001-12-19 HU HU0303530A patent/HUP0303530A3/hu unknown
-
2003
- 2003-05-30 BG BG107863A patent/BG107863A/xx unknown
- 2003-06-02 ZA ZA200304304A patent/ZA200304304B/en unknown
- 2003-06-18 IS IS6851A patent/IS6851A/is unknown
- 2003-06-19 NO NO20032798A patent/NO20032798L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002059124A2 (en) | 2002-08-01 |
| ATE438646T1 (de) | 2009-08-15 |
| BG107863A (en) | 2004-06-30 |
| IS6851A (is) | 2003-06-18 |
| NO20032798L (no) | 2003-08-19 |
| PL366627A1 (en) | 2005-02-07 |
| WO2002059124A3 (en) | 2004-01-08 |
| EE200300303A (et) | 2003-12-15 |
| BR0116348A (pt) | 2004-11-23 |
| RU2003121306A (ru) | 2005-03-10 |
| ES2329553T4 (es) | 2010-12-07 |
| JP2004528290A (ja) | 2004-09-16 |
| ZA200304304B (en) | 2004-09-02 |
| US20040092502A1 (en) | 2004-05-13 |
| JP4386639B2 (ja) | 2009-12-16 |
| EP1399445A2 (en) | 2004-03-24 |
| US6777406B2 (en) | 2004-08-17 |
| NO20032798D0 (no) | 2003-06-19 |
| EP1399445B1 (en) | 2009-08-05 |
| CZ20031707A3 (cs) | 2003-11-12 |
| EP1399445B9 (en) | 2010-07-21 |
| MXPA03005355A (es) | 2004-05-27 |
| CA2432181C (en) | 2009-11-17 |
| KR20030070590A (ko) | 2003-08-30 |
| IL156261A0 (en) | 2004-01-04 |
| HUP0303530A3 (en) | 2012-10-29 |
| HUP0303530A2 (hu) | 2004-01-28 |
| CA2432181A1 (en) | 2002-08-01 |
| DE60139511D1 (de) | 2009-09-17 |
| AU2002246726B2 (en) | 2007-03-01 |
| SK7032003A3 (en) | 2004-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR049443A1 (es) | Derivados de pirrolpiridinas | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
| PE20030890A1 (es) | Cumarinas utiles como biomarcadores | |
| AR077974A1 (es) | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor | |
| AR057984A1 (es) | DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE | |
| AR056764A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| AR040074A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamentos, e intermediarios para la preparacion de dichos compuestos | |
| PE20051039A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| PE20080731A1 (es) | Derivados espirocetales comoinhibidores de sglt2 | |
| AR054416A1 (es) | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. | |
| AR077033A1 (es) | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| MXPA04002526A (es) | Compuestos que contienen lactama y sus derivados como inhibidores del factor xa. | |
| AR052343A1 (es) | Analogos de tetrahidroquinolina como agonistas muscarinicos | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| AR041941A1 (es) | Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1 | |
| AR049883A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
| AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
| CO5570696A2 (es) | 1-amino-alquilciclohexanos insaturados como antagonistas de los receptores nmda, 5ht3 y nicotinico neuronal |